Genetic Clues for Skin Cancer Therapies Springfield Gardens NY

Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.

Local Companies

Gary Brauner
(201) 461-5522
1625 Anderson Ave
Fort Lee, NJ
Michael R Bilkis
(212) 750-3376
515 Madison Ave 2302 Fl
New York, NY
Morton Jacobs
(212) 838-4243
400 E 66Th St
New York, NY
Tobi Klar
(914) 636-2039
150 Lockwood Ave # 20
New Rochelle, NY
Rella Hartman
(718) 852-4646
115 Remsen St
Brooklyn, NY
Philip Lobuono
(201) 339-6681
844 Avenue C
Bayonne, NJ
Stephen L Comite
(212) 557-2600
104 E 40Th St # 402
New York, NY
Pinkas Lebovits
(212) 757-7010
200 W 58Th St # 1
New York, NY
Judy Anderson
(914) 963-0010
984 North Broadway
Yonkers, NY
Peter Milburn
(718) 680-2800
8026 5Th Ave
Brooklyn, NY
Data Provided by:
  

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations.

Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma. Their study is published in the September issue of the journal Nature Genetics.

"We have found what appears to be an Achilles' heel of a sizable share of melanomas," Samuels, an investigator in the cancer genetics branch of the institute's Division of Intramural Research, said in a NIH news release.

The PTK family includes many genes that, when mutated, promote many types of cancer, including brain, gastric and lung malignancies, according to background information provided in the news release. In the new NIH study, one PTK gene that appeared particularly suspicious was the ERBB4 gene. Scientists found ERBB4 mutations in 19 percent of patients' tumors, making it the most frequently mutated PTK gene in melanoma. Additional lab studies found that melanoma cells with the ERBB4 defect were dependent on the mutant gene for their growth.

The researchers also found that two additional PTK genes -- FLT1 and PTK2B -- were mutated in about 10 percent of the tumor samples.

The discoveries could open up new avenues for therapies. For example, the researchers discovered that melanoma cells grew much more slowly when exposed to lapatinib (Tykerb), a chemotherapy drug that inhibits ERBB4. Lapatinib is already in use by some breast cancer patients. The NIH team is planning a clinical trial using lapatinib in patients with metastatic melanoma harboring ERBB4 mutations.

"Though additional work is needed to gain a more complete understanding of these genetic mutations and their roles in cancer biology, our findings open the door to pursuing specific therapies that may prove useful for the treatment of melanoma with ERBB4 mutations," Samuels stated.

More information

The American Cancer Society has more on melanoma.

SOURCE: U.S. National Institutes of Health, news release, Aug. 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com